This article is more than 5 years old. Information may no longer be current.
Independent testing verifies the accuracy of brachytherapy dose delivery
Med Phys. 2009;36(10):4370-4378.
Click Here to Manage Email Alerts
The accuracy of radiation brachytherapy delivery, which may be used to treat patients with age-related macular degeneration, has been independently verified, and the delivery system meets requirements for accuracy established by the Nuclear Regulatory Commission, according to a study.
Researchers sought to quantify the accuracy of the Vidion anti-neovascular therapy system (NeoVista). In the study, the well chamber delivered ionization current through a reference cannula with a variation in the signal between ±0.3% and ±0.5%.
Testing of single use cannulae demonstrated a signal that was an average of 17.8% ± 0.4% of the reference signal. "Measurements presented here also validate the source deployment verification acceptance range," the study authors said.
"Cannula-to-cannula variations for either reference or clinical cannulae were within an acceptable range (less than 1%), except for a single outlying reference cannula that is currently undergoing testing by NeoVista to determine the physical cause of the increased signal," they said.